News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • VIX falls 5.8 points to 20.13 after a U.S.-Iran temporary ceasefire, signaling reduced near-term market volatility.
  • WTI crude plunges after the ceasefire and reopening of the Strait of Hormuz, easing energy-driven cost pressures.
  • U.S. airline and cruise stocks rally, boosted by lower oil and Delta's Q1 earnings beat.
  • Rocket Lab jumps 7% after closing an ATM equity program that raised about $474 million for growth and acquisitions.
  • Intel rises 6% after an analyst raised its price target, citing improved wafer supply at key nodes.
  • IMF finds active conflicts cut output roughly 7% over five years; World Bank trims South Asia 2026 growth to 6.3% citing Middle East conflict.

Latest Articles

BNY Reorganizes Senior Team to Unite Wealth and Managed-Account Businesses

BNY Reorganizes Senior Team to Unite Wealth and Managed-Account Businesses

BNY has reassigned Adam Vos to lead its wealth solutions effort, consolidating BNY Pershing's clearing and custody services - including the Wove platform - with BNY Archer's managed accounts business. The move is part of a broader reshuffle that elevates Jim Crowley to executive vice chair and installs Laide Majiyagbe as global head of markets. The…

BofA Highlights Four Biotech Names Positioned for Potential 2026 Upside

BofA Highlights Four Biotech Names Positioned for Potential 2026 Upside

Bank of America analysts have identified four biotechnology companies they view as top investment ideas for 2026, each supported by specific commercial drivers or upcoming clinical milestones. Their selections - Argenx, KalVista Pharmaceuticals, Ocular Therapeutix and Vertex Pharmaceuticals - carry Buy ratings and price objectives that reflect proj…

Cabaletta Bio: Following the Insider Footsteps Into a High-Short Setup

Cabaletta Bio: Following the Insider Footsteps Into a High-Short Setup

Cabaletta Bio (CABA) is a clinical-stage autoimmune cell therapy name with improving momentum, elevated short interest (about 11 days to cover), and several upcoming clinical and regulatory milestones. With the stock reclaiming key moving averages and still far below its 52-week high, this is a tactically interesting long trade. The setup is not ab…

Oslo OBX Edges Higher as Healthcare, Pharma and Utilities Lead Gains

Oslo OBX Edges Higher as Healthcare, Pharma and Utilities Lead Gains

Norway's benchmark Oslo OBX finished higher on Tuesday, climbing 0.36% as gains in Healthcare Equipment & Services, Pharma Biotech & Life Sciences and Utilities supported the market. Cmb.Tech NV led the index's winners and reached a 52-week high, while Nel ASA and other names declined. Commodity and currency markets moved alongside equities, with c…

Tel Aviv benchmark ticks higher as TA-35 closes at fresh record

Tel Aviv benchmark ticks higher as TA-35 closes at fresh record

Israel’s main equity gauge, the TA-35, closed slightly higher Tuesday, reaching a new all-time peak. Gains in biomedical, technology and banking names supported the advance, while a larger number of issues declined than rose. Selected commodities and currency benchmarks moved modestly, with crude and Brent oil up and the US Dollar Index futures low…

Aumovio to Cut Up to 4,000 R&D Roles as It Reins in Costs

Aumovio to Cut Up to 4,000 R&D Roles as It Reins in Costs

Aumovio SE announced plans to eliminate as many as 4,000 research and development positions worldwide as part of a cost-control plan in a challenging market environment. The company said the reductions will be mostly complete by the end of 2026 and will include a voluntary redundancy program in Germany beginning in March. The move accompanies a tar…

SK Telecom Shares Jump on Reappraisal of Anthropic Stake

SK Telecom Shares Jump on Reappraisal of Anthropic Stake

SK Telecom shares climbed sharply after investors recalibrated the worth of the company’s 2023 investment in AI developer Anthropic. The stock gained 12% to reach $26.93, clearing its prior 52-week peak, as analysts and market participants assessed the possible valuation uplift from Anthropic’s rising implied worth and the implications for sharehol…

Morgan Stanley Sticks with Equalweight on Arrowhead, Cites ARO-DIMER-PA Progress and Redemplo Phase 3 as 2026 Catalyst

Morgan Stanley Sticks with Equalweight on Arrowhead, Cites ARO-DIMER-PA Progress and Redemplo Phase 3 as 2026 Catalyst

Morgan Stanley reaffirmed an Equalweight rating and an $81 price target on Arrowhead Pharmaceuticals (ARWR), signaling roughly 19% upside from the current share price of $67.94. The bank highlighted ongoing progress in the ARO-DIMER-PA program and reiterated that Phase 3 SHASTA-3/4 studies of Redemplo (plozasiran) remain the primary 2026 catalyst f…

Omeros Begins Commercial Shipments of YARTEMLEA; Shares Tick Higher

Omeros Begins Commercial Shipments of YARTEMLEA; Shares Tick Higher

Omeros Corporation's stock edged up after the company said it has completed first commercial shipments of YARTEMLEA (narsoplimab-wuug) to distributors and that transplant centers are beginning to place orders. The therapy, approved by the FDA for adults and children aged two and above, is now being administered to both adult and pediatric patients …

Kepler Cheuvreux Names Five European Capital Goods Picks for 2026

Kepler Cheuvreux Names Five European Capital Goods Picks for 2026

Kepler Cheuvreux has published a sector review of European capital goods, screening 75 companies with market capitalizations above EUR2 billion to identify preferred and least preferred names for 2026. The research highlights concentrated growth in the US and India, strength in data centers and infrastructure-related markets, and mixed prospects ac…

Roth/MKM Boosts Alphabet Price Target to $365, Flags 2026-27 Catalysts

Roth/MKM Boosts Alphabet Price Target to $365, Flags 2026-27 Catalysts

Roth/MKM raised its price target for Alphabet to $365 from $310 and left its Buy rating intact ahead of Alphabet’s fourth-quarter earnings. The firm highlighted multiple potential catalysts in the first half of 2026 - including TPU chip partnerships, Waymo city launches, progress on the Gemini app and likely news around Gemini 4.0 - while noting th…